These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 19821441

  • 1. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
    Ma C, Xie J, Chen Q, Wang G, Zuo S.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD007956. PubMed ID: 19821441
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
    Bohuslavizki KH, Klutmann S, Bleckmann C, Brenner W, Lassmann S, Mester J, Henze E, Clausen M.
    Strahlenther Onkol; 1999 Feb 07; 175(2):57-61. PubMed ID: 10065139
    [Abstract] [Full Text] [Related]

  • 6. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH, Brenner W, Klutmann S, Hübner RH, Lassmann S, Feyerabend B, Lüttges J, Tinnemeyer S, Clausen M, Henze E.
    J Nucl Med; 1998 Jul 07; 39(7):1237-42. PubMed ID: 9669401
    [Abstract] [Full Text] [Related]

  • 7. Radioactive iodine and the salivary glands.
    Mandel SJ, Mandel L.
    Thyroid; 2003 Mar 07; 13(3):265-71. PubMed ID: 12729475
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
    Riley P, Glenny AM, Hua F, Worthington HV.
    Cochrane Database Syst Rev; 2017 Jul 31; 7(7):CD012744. PubMed ID: 28759701
    [Abstract] [Full Text] [Related]

  • 9. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH, Klutmann S, Jenicke L, Kröger S, Buchert R, Mester J, Clausen M.
    Cancer Biother Radiopharm; 1999 Oct 31; 14(5):337-47. PubMed ID: 10850318
    [Abstract] [Full Text] [Related]

  • 10. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model.
    Bohuslavizki KH, Klutmann S, Jenicke L, Brenner W, Feyerabend B, Henze E, Clausen M.
    Int J Radiat Oncol Biol Phys; 1999 Aug 01; 45(1):181-6. PubMed ID: 10477022
    [Abstract] [Full Text] [Related]

  • 11. Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
    Torun N, Muratli A, Serim BD, Ergulen A, Altun GD.
    Curr Med Imaging Rev; 2019 Aug 01; 15(4):395-404. PubMed ID: 31989909
    [Abstract] [Full Text] [Related]

  • 12. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
    Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, Kim JS.
    Thyroid; 2008 Mar 01; 18(3):325-31. PubMed ID: 18341378
    [Abstract] [Full Text] [Related]

  • 13. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
    Kutta H, Kampen U, Sagowski C, Brenner W, Bohuslavizki KH, Paulsen F.
    Strahlenther Onkol; 2005 Apr 01; 181(4):237-45. PubMed ID: 15827693
    [Abstract] [Full Text] [Related]

  • 14. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Auttara-Atthakorn A, Sungmala J, Anothaisintawee T, Reutrakul S, Sriphrapradang C.
    Front Endocrinol (Lausanne); 2022 Apr 01; 13():960265. PubMed ID: 36105397
    [Abstract] [Full Text] [Related]

  • 15. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J.
    Thyroid; 2013 May 01; 23(5):609-16. PubMed ID: 23153322
    [Abstract] [Full Text] [Related]

  • 16. Association of Xerostomia and Ultrasonographic Features of the Major Salivary Glands After Radioactive Iodine Ablation for Papillary Thyroid Carcinoma.
    Soo Roh S, Wook Kim D, Jin Baek H.
    AJR Am J Roentgenol; 2016 Nov 01; 207(5):1077-1081. PubMed ID: 27504709
    [Abstract] [Full Text] [Related]

  • 17. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F.
    Cochrane Database Syst Rev; 2010 Nov 10; 2010(11):CD008302. PubMed ID: 21069705
    [Abstract] [Full Text] [Related]

  • 18. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.
    Upadhyaya A, Zhou P, Meng Z, Wang P, Zhang G, Jia Q, Tan J, Li X, Hu T, Liu N, Wang S, Liu X, Wang H, Zhang C, Zhao F, Yan Z, Wang X, Zhang X, Zhang W.
    Nucl Med Commun; 2017 Nov 10; 38(11):891-903. PubMed ID: 28806348
    [Abstract] [Full Text] [Related]

  • 19. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
    Caglar M, Tuncel M, Alpar R.
    Clin Nucl Med; 2002 Nov 10; 27(11):767-71. PubMed ID: 12394122
    [Abstract] [Full Text] [Related]

  • 20. The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial.
    Amini S, Golshani M, Moslehi M, Hajiahmadi S, Askari G, Iraj B, Bagherniya M.
    Trials; 2023 Aug 07; 24(1):501. PubMed ID: 37550760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.